Pulmonx
Minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.
Launch date
Employees
Market cap
€296m
Enterprise valuation
€243m (Public information from Sep 2024)
Share price
$8.58 LUNG
Redwood City California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 32.7m | 48.4m | 53.7m | 68.7m | 82.6m | 98.4m | 118m |
| % growth | - | 48 % | 11 % | 28 % | 20 % | 19 % | 20 % |
| EBITDA | (28.8m) | (47.5m) | (57.5m) | (55.5m) | (57.5m) | (54.5m) | (49.0m) |
| % EBITDA margin | (88 %) | (98 %) | (107 %) | (81 %) | (70 %) | (55 %) | (42 %) |
| Profit | (32.2m) | (48.7m) | (58.9m) | (60.8m) | (64.9m) | (63.8m) | (53.8m) |
| % profit margin | (98 %) | (101 %) | (110 %) | (89 %) | (79 %) | (65 %) | (46 %) |
| EV / revenue | 69.0x | 21.1x | 3.7x | 7.1x | 3.5x | 2.9x | 2.4x |
| EV / EBITDA | -78.3x | -21.5x | -3.5x | -8.8x | -5.0x | -5.3x | -5.8x |
| R&D budget | 7.5m | 13.1m | 15.4m | 18.1m | - | - | - |
| R&D % of revenue | 23 % | 27 % | 29 % | 26 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$20.0m | Series B | ||
| N/A | $7.0m | Debt | |
| N/A | $2.9m | Early VC | |
$32.0m | Series C | ||
$10.0m | Early VC | ||
$20.0m | Debt | ||
$30.0m | Series F | ||
$65.0m | Growth Equity VC | ||
$66.0m | Series H | ||
| N/A | $190m | IPO | |
| Total Funding | €212m | ||
Recent News about Pulmonx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.